Absolutely.

We distill complex reimbursement issues into clean, investor-ready messaging. Slides, timelines, and talking points included.

We specialize in U.S. Reimbursement - but work globally.

If the U.S. market factors into your launch strategy or investor pitch, we're the partner to guide you through it.

Yes — and more.

We map out strategies across Medicare, Medicare Advantage, Medicaid, and Commercial payers. Most success stories involve a hybrid path.

Not at all.

Most of our clients are lean teams. We serve as your fractional reimbursement strategist - giving you the roadmap without the headcount.

No - you're right on time.

Engaging early, even pre-clinical or pre-regulatory, gives you time to align your evidence and messaging with what payers will eventually demand. It's how our savviest clients avoid costly missteps later.